Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study
Authors:
- Karl BordeauKBKarl Bordeau
- Morgan MichaletMMMorgan Michalet
- Aïcha KeskesAKAïcha Keskes
- Simon ValdenaireSVSimon Valdenaire
- Pierre DebuirePDPierre Debuire
- Marie CantaloubeMCMarie Cantaloube
- Morgane CabailléMCMorgane Cabaillé
- William JacotWilliam Jacot
- Roxana DraghiciRDRoxana Draghici
- Sylvain DemontoySDSylvain Demontoy
- Xavier QuantinXQXavier Quantin
- Marc YchouMYMarc Ychou
Open Access
- 2 February 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (3) , 1183
Abstract
Liver stereotactic body radiotherapy (SBRT) is a local treatment that provides good local control and low toxicity. We present the first clinical results from our prospective registry of stereotactic MR-guided radiotherapy (MRgRT) for liver metastases. All patients treated for liver metastases were included in this prospective registry study. Stereotactic MRgRT indication was confirmed by multidisciplinary specialized tumor boards. The primary endpoints were acute and late toxicities. The secondary endpoints were survival outcomes (local control, overall survival (OS), disease-free survival, intrahepatic relapse-free survival). Twenty-six consecutive patients were treated for thirty-one liver metastases between October 2019 and April 2022. The median prescribed dose was 50 Gy (40–60) in 5 fractions. No severe acute MRgRT-related toxicity was noted. Acute and late gastrointestinal and liver toxicities were low and mostly unrelated to MRgRT. Only 5 lesions (16.1%) required daily adaptation because of the proximity of organs at risk (OAR). With a median follow-up time of 17.3 months since MRgRT completion, the median OS, 1-year OS and 2-year OS rates were 21.7 months, 83.1% (95% CI: 55.3–94.4%) and 41.6% (95% CI: 13.5–68.1%), respectively, from MRgRT completion. The local control at 6 months, 1 year and 2 years was 90.9% (95% CI: 68.3–97.7%). To our knowledge, we report the largest series of stereotactic MRgRT for liver metastases. The treatment was well-tolerated and achieved a high LC rate. Distant relapse remains a challenge in this population.Keywords
This publication has 22 references indexed in Scilit:
- Local Control After Stereotactic Body Radiation Therapy for Liver TumorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized TrialJournal of Clinical Oncology, 2020
- Validation of an MR-guided online adaptive radiotherapy (MRgoART) program: Deformation accuracy in a heterogeneous, deformable, anthropomorphic phantomRadiotherapy and Oncology, 2020
- The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastasesBMC Cancer, 2019
- A Multi-Institutional Experience of MR-Guided Liver Stereotactic Body Radiation TherapyAdvances in Radiation Oncology, 2019
- Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic reviewRadiotherapy and Oncology, 2018
- Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2016
- Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient SelectionInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved ChemotherapyJournal of Clinical Oncology, 2009
- Abdominal organ motion measured using 4D CTInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006